{"pmid":32336674,"title":"COVID-19 emergency responders in FDA's Center for Drug Evaluation and Research.","text":["COVID-19 emergency responders in FDA's Center for Drug Evaluation and Research.","J Am Pharm Assoc (2003)","Gormley, Lieutenant Commander Andrea","Ngan, Commander Kelly","32336674"],"journal":"J Am Pharm Assoc (2003)","authors":["Gormley, Lieutenant Commander Andrea","Ngan, Commander Kelly"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32336674","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.japh.2020.04.010","topics":["Treatment"],"weight":1,"_version_":1665264685561151488,"score":8.574329,"similar":[{"pmid":32251768,"title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.","text":["The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.","Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect approximately 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.","Antiviral Res","Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M","32251768"],"abstract":["Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect approximately 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans."],"journal":"Antiviral Res","authors":["Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251768","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104787","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136233123840,"score":71.696915},{"pmid":32289216,"title":"Drug Evaluation during the Covid-19 Pandemic.","text":["Drug Evaluation during the Covid-19 Pandemic.","N Engl J Med","Rome, Benjamin N","Avorn, Jerry","32289216"],"journal":"N Engl J Med","authors":["Rome, Benjamin N","Avorn, Jerry"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32289216","week":"202016|Apr 13 - Apr 19","doi":"10.1056/NEJMp2009457","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636391603044353,"score":67.202065},{"pmid":32251634,"title":"Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.","text":["Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.","AIMS: In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics. MATERIALS AND METHODS: Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated. KEY FINDINGS: COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV. SIGNIFICANCE: The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment.","Life Sci","Kandeel, Mahmoud","Al-Nazawi, Mohammed","32251634"],"abstract":["AIMS: In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics. MATERIALS AND METHODS: Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated. KEY FINDINGS: COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV. SIGNIFICANCE: The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment."],"journal":"Life Sci","authors":["Kandeel, Mahmoud","Al-Nazawi, Mohammed"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251634","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.lfs.2020.117627","keywords":["2019-Novel Coronavirus","COVID-19, 2019-nCoV","Main protease","Molecular modeling","Wuhan Coronavirus"],"source":"PubMed","locations":["COVID+19","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136214249472,"score":50.889896},{"pmid":32330482,"title":"Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.","text":["Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.","Antiviral Res","Bray, Mike","Rayner, Craig","Noel, Francois","Jans, David","Wagstaff, Kylie","32330482"],"journal":"Antiviral Res","authors":["Bray, Mike","Rayner, Craig","Noel, Francois","Jans, David","Wagstaff, Kylie"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330482","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.antiviral.2020.104805","source":"PubMed","weight":0,"_version_":1664996914856198144,"score":45.99038},{"pmid":32308266,"pmcid":"PMC7147498","title":"Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus.","text":["Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus.","Design and development of an effective drug to combat the 2019 novel coronavirus remains a challenge. Therefore, it is of interest to study the binding features of 1615 FDA approved drugs with the recently known 2019-nCoV main protease structure having high sequence homology with that from SARS-CoV. We document the binding features of top 10 drugs with the target protein. We further report that Conivaptan and Azelastine are mainly involved in hydrophobic interactions with active site residues. Both drugs can maintain close proximity to the binding pocket of main protease during simulation. However, these data need further in vitro and in vivo evaluation to repurpose these two drugs against 2019-nCoV.","Bioinformation","Odhar, Hasanain Abdulhameed","Ahjel, Salam Waheed","Albeer, Ali A Mohammed Ali","Hashim, Ahmed Fadhil","Rayshan, Ali Mahmood","Humadi, Suhad Sami","32308266"],"abstract":["Design and development of an effective drug to combat the 2019 novel coronavirus remains a challenge. Therefore, it is of interest to study the binding features of 1615 FDA approved drugs with the recently known 2019-nCoV main protease structure having high sequence homology with that from SARS-CoV. We document the binding features of top 10 drugs with the target protein. We further report that Conivaptan and Azelastine are mainly involved in hydrophobic interactions with active site residues. Both drugs can maintain close proximity to the binding pocket of main protease during simulation. However, these data need further in vitro and in vivo evaluation to repurpose these two drugs against 2019-nCoV."],"journal":"Bioinformation","authors":["Odhar, Hasanain Abdulhameed","Ahjel, Salam Waheed","Albeer, Ali A Mohammed Ali","Hashim, Ahmed Fadhil","Rayshan, Ali Mahmood","Humadi, Suhad Sami"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32308266","week":"202017|Apr 20 - Apr 26","doi":"10.6026/97320630016236","keywords":["2019-ncov","docking","dynamics simulation","main protease","repurposing"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"e_drugs":["conivaptan","azelastine"],"_version_":1664632501440610304,"score":45.69864}]}